Roibeard O’hEineachain
Published: Thursday, September 30, 2021
New EP2 antagonist eye drop provides IOP reduction similar to prostaglandin-analogues. Roibeárd Ó hÉineacháin reports from the 9th World Glaucoma E-Congress.
A new non-prostaglandin eye drop formulation called omidenepag isopropyl (EYBELIS®, Santen) has an IOP-lowering effect comparable to that of latanoprost for primary open-angle glaucoma (POAG) and ocular hypertensive patients, but without the cosmetic side effects, said Makoto Aihara MD, PhD.
“Omidenepag isopropyl could be the new first-line drug for glaucoma,” he continued.
Dr Aihara noted that omidenepag isopropyl (OMDI) is a prodrug hydrolysed in the eye to its active form, omidenepag—a selective, non-prostaglandin, prostanoid EP2 agonist. Omidenepag has a novel mechanism of action that lowers IOP by increasing aqueous humour outflow through both uveoscleral and trabecular pathways.
Unlike prostaglandin F2α analogues currently in clinical use, omidenepag has no measurable effect on the FP receptor in the eye, eliminating the risk of FP-mediated adverse events such as eyelash growth and prostaglandin-associated periorbitopathy (PAP). OMDI has been approved for POAG treatment in Japan, Korea, and Taiwan, he noted.
Several trials have confirmed OMDI’s safety and efficacy. For example, in phases one and two of the multicentre randomised controlled trial, IOP decreased from 23.78mmHg to 17.81mmHg after four weeks of treatment with OMDI 0.002% in 94 POAG patients, and 23.40mmHg to 16.96 mmHg after the same length of treatment in 96 patients randomised to latanoprost.
Dr Aihara noted that OMDI’s side effect profile is different from latanoprost. The more common adverse events among patients receiving OMDI were conjunctival hyperaemia (24.5% versus 10.4%) and corneal thickening (11.7% versus 1.0%), whereas punctuate keratitis was less common (0% versus 7.3%) than in eyes treated with latanoprost.
A phase three study evaluating long-term IOP reduction achieved with OMDI in patients with POAG or OHT supported the study findings. It showed that after 52 weeks of treatment with OMDI 0.002%, mean IOP decreased by 2.4mmHg (19.5%) in 48 patients with a baseline IOP of 16mmHg to 22mmHg and 5.64mmHg (23%) in patients with baseline IOP of 22mmHg to 34mmHg.
There were no reports of cosmetic adverse events like PAP syndrome or increased pigmentation of the iris, eyelid, and eyelashes throughout the study. Moreover, in an ongoing study involving 12 POAG patients with PAP syndrome who were switched to OMDI 0.002% from a prostaglandin analogue, deepening of the upper eyelid sulcus improved in six patients, and a flattening of the lower eyelid bags improved in three after 12 months.
Makoto Aihara MD, PhD is Chair and Professor of Ophthalmology, University of Tokyo, Japan
aihara-tky@umin.ac.jp; macaihara1126@gmail.com
Tags: glaucoma
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
Read more...
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Read more...
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Read more...
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Read more...
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Read more...
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
Read more...
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Read more...
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Read more...
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Read more...
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.
Read more...